Epigenetic Approaches to the Treatment of Renal Cell Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Seong Hwi | - |
dc.contributor.author | Lee, Jiyoung | - |
dc.contributor.author | Jang, Eun Bi | - |
dc.contributor.author | Park, Sung Yul | - |
dc.contributor.author | Moon, Hong Sang | - |
dc.contributor.author | Yoon, Young Eun | - |
dc.date.accessioned | 2022-07-06T02:07:14Z | - |
dc.date.available | 2022-07-06T02:07:14Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 1598-8341 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138398 | - |
dc.description.abstract | To summarize the epigenetics in renal cell carcinoma (RCC) and discuss the potential use of epigenetic modifiers as RCC biomarkers and treatments. Pertinent articles available on PubMed and google scholar database pertaining to kidney cancer and epigenetics were reviewed. Metastatic RCC is one of the most difficult cancers to treat. Although RCC is commonly known to be caused by VHL mutations, it is not enough to understand the complete pathophysiology of RCC. Epigenetic factors can play a fundamental role in the pathogenesis of RCC. Epigenetic regulators are classified as epigenetic writers, readers, and erasers according to their role. In this review, we discuss the potential role of epigenetic regulators as a biomarker for RCC. We also review medications that target epigenetic enzymes and are currently tried in RCC therapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한비뇨기종양학회 | - |
dc.title | Epigenetic Approaches to the Treatment of Renal Cell Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Sung Yul | - |
dc.contributor.affiliatedAuthor | Moon, Hong Sang | - |
dc.contributor.affiliatedAuthor | Yoon, Young Eun | - |
dc.identifier.doi | 10.22465/kjuo.2020.18.2.78 | - |
dc.identifier.bibliographicCitation | 대한비뇨기종양학술지, v.18, no.2, pp.78 - 90 | - |
dc.relation.isPartOf | 대한비뇨기종양학술지 | - |
dc.citation.title | 대한비뇨기종양학술지 | - |
dc.citation.volume | 18 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 78 | - |
dc.citation.endPage | 90 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002618162 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Epigenetics | - |
dc.subject.keywordAuthor | Kidney cancer | - |
dc.identifier.url | https://www.kjuo.or.kr/journal/view.php?doi=10.22465/kjuo.2020.18.2.78 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.